Pegaptanib, the first therapeutic aptamer approved by the US FDA, is a polyethyleneglycolated anti-VEGF aptamer used for the treatment of age-related macular degeneration (AMD) [84]. The gene discussed is VEGFA; the disease is age-related macular degeneration.